Non-Invasive Prenatal Testing Service

Screen Shot 2016-07-11 at 7.33.03 AM

What is non-invasive prenatal testing (NIPT) ?

When you’re pregnant, your blood contains fragments of your baby’s DNA. A non-invasive prenatal test (NIPT) is a new type of screening test that analyses this circulating DNA in a sample of your blood to predict the risk of your baby having certain genetic abnormalities. Collecting your blood sample for NIPT poses no threat to your baby. inqaba biotec offers through its partner Sequenom laboratories 3 distinct NIPT tests:

  • MaterniT GENOME
  • MaterniT21 PLUS
  • VisibiliT
a

 

Choosing the right non-invasive prenatal test

MaterniT Genome-Logo

MT21-PLUS-Logo-®-RGB

VisibiliT-Logo-2c-PMS639-BLUE-e1443623573892


 

 About Sequenom Laboratories

Non-invasive prenatal testing (NIPT) was pioneered by Sequenom Laboratories in 2011, and since then, several hundred thousand pregnant women worldwide have benefited. Many have avoided potentially unnecessary invasive procedures while still gaining important information about the health of their pregnancies.

With Sequenom Laboratories’ recent scientific advancements, they have enabled non-invasive prenatal testing to reach even more pregnant women looking for relevant genetic information about their pregnancy.

Sequenom Laboratories is the first provider to offer three distinct non-invasive prenatal testing choices with the MaterniT GENOME, MaterniT21 PLUS and the VisibiliT laboratory-developed tests. MaterniT GENOME is the most comprehensive NIPT to date and has shown to deliver up to 25% more clinically relevant chromosomal information than other NIPT.

 

Contact

For more information and/or to order a kit, please contact us on:

NIPT@inqababiotec.co.za

Availability of MaterniT Genome and MateniT21 Plus

Info for doctors

Sample Reports

VisibiliT

MaterniT21PLUS 

MaterniT Genome

Genetic counselling

Genetic counselling support is available for patients with positive test results.

__________________________________________________________________________________

References

  1. Palomaki GE, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13, as well as Down syndrome: An international collaborative study. Genet Med. 2012;14(3):296-305.
  2. Mazloom AR, Dzakula Z, Oeth P, Wang H, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn. 2013;33(6):591-597.
  3. Canick JA, et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat Diagn. 2012;32(8):730-734.
  4. Zhao C, et al. Detection of fetal subchromosomal abnormalities by sequencing CCF from maternal plasma. Poster presented at the ACMG Annual Clinical Genetics Meeting; March 2014; Nashville, TN.
  5. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin; Number 77, January 2007.
  6. Kim S, et al. Application of risk-score analysis to low-coverage sequencing data for noninvasive detection of trisomy 21 and trisomy 18. Poster presented at the 18th International Conference on Prenatal Diagnosis and Therapy; July 2014; Brisbane, Australia.

Contact Details

Southern Africa

  • Inqaba Biotechnical Industries (Pty) Ltd.
  • PO Box 14356, Hatfield 0028
  • Pretoria, South Africa

  • Tel: +27 12 343 5829
  • Fax: +27 86 677 8409
  • E-mail: info@inqababiotec.co.za

East Africa

  • inqaba biotec East Africa Ltd.
  • PO Box 1846
  • Nairobi 00606, Kenya

  • Tel: +254 735 370 693
  • Fax: +27 86 677 8409
  • E-mail: info@inqababiotec.co.ke

West Africa

  • inqaba biotec West Africa Ltd.
  • PMB 5320, Oyo Road, Ibadan 200001
  • Oyo State, Nigeria

  • Tel: +‎234 805 882 7272
  • Fax: +27 86 677 8409
  • E-mail: info@inqababiotec.ng